NCT02661815View on ClinicalTrials.gov

A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 15, 2016

Primary Completion Date

June 28, 2017

Study Completion Date

July 28, 2017

Conditions
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma
Interventions
DRUG

Paclitaxel

Please see arm/group description.

DRUG

Ricolinostat

Please see arm/group description.

DRUG

Bevacizumab

Please see arm/group description.

Trial Locations (2)

02114

Massacusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER